Probiotic in diabetes

The global prevalence of both T1D and T2D continues to rise each year. Current estimates indicate that about 465 million adults between 20 and 79 years of age throughout the world are currently living with diabetes, with up to 578 and 700 million projected to be diagnosed by 2030 and 2045, respectively.

Despite recent advancements in anti-diabetic treatments, a significant proportion of patients continue to experience suboptimal glycemic control. Among various novel strategies for glycemic control, targeting the gut microbiota through probiotics and other therapeutics has been proposed as a novel approach to managing diabetes.

In T1D, which refers to insulin deficiency, and T2D, which occurs due to insulin resistance, specific alterations in the composition and function of the gut microbiota, which are collectively referred to as gut dysbiosis, have been reported. Probiotics are live microorganisms are associated with numerous health benefits through their ability to restore gut microbiota homeostasis, improve the integrity of the gastrointestinal (GI) tract, and reduce inflammation.

Synbiotics, which are combinations of probiotics and prebiotics, are also gaining attention in the field of diabetes management to increase the growth and functions of beneficial microorganisms present within the GI tract.

The current meta-analysis revealed that probiotic and synbiotic supplementation is associated with significant improvements in fasting plasma glucose, serum insulin, and HbA1C levels.

Multispecies formulations were associated with superior effectiveness in improving HbA1C levels compared to monospecies formulations. This observation emphasizes the importance of multispecies formulations in achieving persistent glycemic control.

Regarding the different types of bacterial species used in probiotic formulations, certain Lactobacillus strains and Bifidobacterium lactis were associated with pronounced effects, especially in multispecies formulations. Thus, the therapeutic efficacy of probiotic interventions for managing diabetes may be strain-specific.

The study findings emphasize the potential importance of both probiotics and synbiotics as complementary interventions in diabetes management. Nevertheless, future studies that consider multiple variables, such as strain types and geographical factors, are needed to better understand the efficacy of probiotics and synbiotics in the management of T1D and T2D.

One of the synbiotic products of Zist Takhamtir, which is a suitable option for people with diabetes, is FamiLact 2 Plus. This product has strains that affect blood factors in diabetes and also due to Being synbiotic and their more proven effects in diabetes compared to probiotic products is a suitable and efficient choice for these people.

References:

Baroni, I., Fabrizi, D., Luciani, M., et al. (2024). Probiotics and synbiotics for glycemic control in diabetes: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition. doi:10.1016/j.clnu.2024.03.006